NCT05410275RecruitingPhase 3
Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients
Chronic Anticoagulation in End-stage Renal Disease Patients: Pharmacokinetics and Pharmacodynamic of a Reduced Dose Regimen of Rivaroxaban
Source: ClinicalTrials.gov · Last updated 18 Jun 2026
Brief summary (registry, in English)
Atrial fibrillation is the most frequent cardiac rhythm disorder and its prognosis is essentially marked by the risk of embolic events. Its treatment is based on long-term oral anticoagulant therapy according to the risk of embolic events assessed by risk scores such as the CHA2DS2-Vasc score, but this prescription is associated with a risk of hemorrhagic events that must be taken into consideration when deciding on the treatment for a given patient. There are two categories of validated oral anticoagulant treatments for the prevention of embolic events in atrial fibrillation: antivitamin K agents, which have long been the reference treatment but are restrictive and difficult to use because of a narrow therapeutic window, and direct oral anticoagulants, which are now the first-line treatment but have not been evaluated in phase II and III studies in patients with severe renal failure. End-stage renal disease (clearance \<15 mL/min/1.73m2), particularly at the dialysis stage, is a risk factor for cardiovascular disease in its own right, and a significant number of patients develop atrial fibrillation. Given the co-morbidities associated with renal failure, in particular hypertension, patients with renal failure undergoing dialysis and suffering from atrial fibrillation are generally at a higher risk of embolism than patients without renal failure, but also at a higher risk of bleeding. Thus, if the indication for prescribing oral anticoagulant therapy is clear in this population, the associated bleeding complications are also more frequent and more serious in these patients who have regular vascular accesses in the context of hemodialysis. There is thus a real need for reliable therapeutic alternatives with a better benefit/risk ratio than antivitamins K. Translated with www.DeepL.com/Translator (free version)
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 2 Feb 2022
- Start date
- 8 Jan 2025
- Primary completion date
- 30 Jan 2027
- Lead sponsor
- University Hospital, Tours
- Diseases
- Chronic kidney disease
- NCT number
- NCT05410275
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 10
- From 8 Jan 2025 to the primary completion date, 30 Jan 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Ischemic stroke within 30 days prior to inclusion
- Surgery within 30 days prior to inclusion
- Patients already participating in an ongoing study or who have participated in a study that ended less than 30 days prior to the inclusion date.
Other illness
- Any indication for long-term oral anticoagulation (atrial fibrillation, venous thromboembolic disease, mechanical valve prostheses, intracardiac thrombosis, etc.)
- Uncontrolled hypertension (BP \> 180/110 mmHg)
- High-risk bleeding condition in addition to renal failure (such as known coagulation disorder, thrombocytopenia (\< 100G/L), active neoplasia of the digestive or urinary tract, or presence of intracranial vascular malformation)
- Severe hepatic impairment
- Contraindication to the administration of an anticoagulant treatment such as anti-phospholipid antibody syndrome
- Known allergy to rivaroxaban or to one of its excipients (lactose monohydrate)
Lab values
- Double anti-platelet aggregation for any reason or an aspirin dose greater than 160 mg/day
Age
- History of major unprovoked hemorrhage (leading to hospitalization or transfusion) regardless of age
- Pregnant or breastfeeding women, women of childbearing age without effective contraception
Other
- Use of strong CYP3A4 inducers, including rifampin, St. John's Wort, carbamazepine, phenytoin, phenobarbital
- Non-compliant patients
- Patients under guardianship or conservatorship
Who the study is looking for
- Adult patient ≥ 18 years of age,
- Chronic hemodialysis patient for at least 3 months,
- Affiliated or beneficiary of a social security plan,
- Having signed a written and informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| 02-TOURS Coordinator of this site? Confirm its status | Tours | France | Recruiting |
| 01-Arauco Coordinator of this site? Confirm its status | Tours | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.